Sino Biopharmaceutical Ltd ($1177) - buy or sell? Stock discussion, ideas, forum

Sino Biopharmaceutical Ltd

Sino Biopharmaceutical Limited, through its subsidiaries, researches, develops, produces, and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis.

Industry: Pharmaceuticals

Ticker	Exchange	ISIN	Name
$1177	HKEx Main Board	KYG8167W1380	Code: 1177

Recent news

TAI Ping Carpet International Ltd revenue jumped on 34.8% while EBITDA Margin decreased on 2.8 pp from 9.9% to 7.1%

Vision Fame International Holding Ltd revenue growth accelerated from 2.3% in FY2019 to 405% in FY2020

Kantone Holdings Ltd reports 13.0% EBITDA growth in 2020 and 0.61 pp EBITDA Margin growth from 5.7% to 6.3%

Heng Tai Consumables Group Ltd revenue dropped on 35.5% and EBITDA Margin dropped on 19.0 pp from -27.6% to -46.6%

Yat Sing Holdings Ltd revenue decreased on 8.4% and EBITDA Margin decreased on 2.2 pp from -1.7% to -3.9%

Art Textile Technology International Co Ltd Net Debt / EBITDA surged on 82.8x from 3.9x to 86.8x in 2020 while Revenue dropped on 24.7%

China Zenith Chemical Group Ltd revenue dropped on 39.8% while EBITDA Margin surged on 93.4 pp from -149% to -55.4%

Odella Leather Holdings Ltd revenue returned to growth in FY2020: increased 60.4% vs. 48.6% decline a year earliner

New World Development Co Ltd Net Income dropped on 85.3% and Revenue dropped on 23.1%

NWS Holdings Ltd reports 80.3% Net Income decline in 2020 and 3.4% Revenue decline

Twit about 1177 stock

Share your investment idea or question on Sino Biopharmaceutical Ltd stock:

Latest twits on Sino Biopharmaceutical Ltd (1177)

No twits yet. Be the first to post!

Have a question about 1177? Ask and other investors will be eager to help you.

Have an idea about 1177? Share it with other investors.

Sino Biopharmaceutical Ltd news

13/03/2017 Sino Biopharmaceutical Ltd reports 12.0% EBITDA growth and 8.8% Revenue growth

06/04/2016 Eye on Sino Biopharmaceutical Ltd as a growth stock

30/03/2016 Sino Biopharmaceutical Ltd EBITDA jumped on 25.3% in 2015 and EBITDA Margin increased slightly on 1.4 pp from 21.4% to 22.8%

01/04/2015 Sino Biopharmaceutical Ltd demonstrated healthy growth in recent years

Sino Biopharmaceutical Ltd stock price chart

Sino Biopharmaceutical Ltd financials

mln. HKD	FY2010	FY2011	FY2012

Revenue	4,086	5,782	7,497
EBITDA	1,154	1,087	1,603
Net income	566.9	462.8	890.8
CAPEX	426.8	286.0	331.9
Debt	155.3	85.139	41.048
Cash	1,619	2,018	2,495